An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML)
Latest Information Update: 08 Oct 2021
At a glance
- Drugs BMS 833923 (Primary) ; Dasatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record. (2016-01-25)
- 01 Aug 2017 Results evaluating cardiovascular ischaemic event rates in dasatinib treated patients using patient data from NCT00103701, NCT00101647, NCT00101816, NCT00101660, NCT00101595, NCT00103844, NCT00123474, NCT00123487, NCT00481247, NCT00529763, NCT01357655, NCT00744497 trials and and comparing it with external reference populations published in the Annals of Hematology
- 24 Jan 2017 Status changed from completed to discontinued.